Erste Group downgraded Boston Scientific (BSX) to Hold from Buy. The company’s sales growth will be lower in 2026 than in 2025 and stock is expensive relative to peers, the analyst tells investors in a research note. The firm sees limited share upside from current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $136 from $133 at Barclays
- Top 3 Trending Stocks, According to Analysts – 10/1/2025
- Boston Scientific call volume above normal and directionally bullish
- Boston Scientific price target raised to $129 from $125 at Truist
- Elutia closes sale of its BioEnvelope business to Boston Scientific for $88M